

L'Union Médicale Balkanique Balkan Medical Union



Balkanska Medicinska Unija



32nd
Balkan
Medical
Week

32^{ème}
Sémaine
Medicale
Balkanique



21-23. September 2012. University of Nis Nis, Serbia



32nd BALKAN MEDICAL WEEK - Nis, SERBIA 32eme SEMAINE MEDICALE BALKANIQUE - Nis, SERBIA

OFFICERS OF THE BALKAN MEDICAL UNION

International Secretary General: professor Vasile Cândea, Romania

Albania: Prof. Ylli Ppa, President, Tirana Prof. Mentor Petrela, Secretary General, Tirana

Bulgaria: Prof. Venko Alexandrov, President, Sofia Prof. Fanny Ribarova, Secretary General, Sofia

Cyprus: Dr Vassos Lyssarides, President, Nicosie Dr Kaya Bekiroglu, Vice-president, TRNC

Greece: Prof. Niki Agnantis, former president, Ioannina Prof. Ioannis Karaitianos, President, Athens Dr Anastasios Thanos, Secretary General, Athens

Republic of Moldova: Prof. Gheorghe Ciobanu, President, Chisinau Prof. Minodora Mazur, Secretary General, Chisinau

Romania: Prof. Nicolae Angelescu, President, Bucarest Prof. Vasile Burlui, Vice-president, Iasi Prof. Ioan Lascăr, Vice-president, Bucarest Prof. Mircea Grigorescu, Vice-president, Cluj Dr Ioan Ieţcu, Vice-president, Suceava Adriana Milea, Executive Director

Serbia: Prof. Vladmila Bojanić, President, Niš Prof. Snažana Jančić, Secretary General, Kragujevac

Turkey: Prof. Somer Ones, former president, Istanbul Prof. Sabri Ergüney, President, Istanbul Prof. Ali Haydar Taspinar, Vice-president, Istanbul Prof. Ertugrul Gazioglu, Treasurer, Istanbul

ORGANISING COMMITTEE:

President: Prof. Bojanić V,

Prof. Đinđić B

Doc. Bojanić Z

Prof. Šmelcerović A

Prof. Savić T

Prof. Najman S

Prof. Sokolović D

Prof. Milojković M

Doc. Lazović M

Adriana Milea

SCIENTIFIC COMMITTEE

CHAIRMAN OF THE SCIENTIFIC COMMITTEE - PREDSEDNIK NAUČNOG ODBORA MEMBERS OF THE SCIENTIFIC COMMITTEE - ČLANOVI NAUČNOG ODBORA

Prof. dr Vasil Candea

Prof.dr Yves Juillet

Prof. Emmeritus Niki Agnantis

Prof. Emmeritus George Chaldakov

Prof.dr Milorad Mitković

Prof. dr Vladislav Stefanović

Prof. dr Dušica Pavlović

Prof. Fanny Ribarova

Prof.dr Marina Deljanin Ilić

Prof.dr Snežana Jančić

Prof.dr Slobodan Janković

Prof.dr Stevo Najman

Prof.dr Dragan Đurić

Prof.dr Vladmila Bojanić

Prof.dr Vlada Janković

Doc.dr Zoran Bojanić

Prof.dr Dusica Stojanovic

Prof.dr Stojan Radić

Prof.dr Sonja Radenković

Acknowledgments: The financial support of this work by Ministry of Education and Science of the public of Serbia (Grant No. 172044) and National Science Fund of Bulgaria (young researchers DMU-03/66) is gratefully acknowledged.

P64 6-(propan-2-YL)-3-methyl-morpholine-2,5-dione, a novel xanthine oxidase inhibitor

HE RE HE G

日七日日日

Šmelcerović Ž¹, Yancheva D², Daskalova L², Cherneva E³, Šmelcerović A⁴, Petronijević Ž⁵, Kocić

¹Center for Biomedicinal Science, Faculty of Medicine, University of Niš, Niš, Serbia

- ² Institute of Organic Chemistry with Center of Phytochemistry, Bulgarian Academy of Sciences, S Bulgaria
- ³ Department of Chemistry, Faculty of Pharmacy, Medical University of Sofia, Bulgaria

⁴ Department of Chemistry, Faculty of Medicine, University of Niš, Niš, Serbia

⁵ Faculty of Technology, University of Niš, Leskovac, Serbia

⁶ Institute of Biochemistry, Faculty of Medicine, University of Niš, Niš, Serbia

Introduction. Cyclodepsipeptides are known to exhibit a broad spectrum of biological activities present a great potential for pharmacological application. A novel didepsipeptide member of the 6-(propan-2-yl)-3-methyl-morpholine-2,5-dione, was synthesized and its structure was confirmal IR, ¹H and ¹³C NMR spectral data.

Aims. In the present study the above mentioned compound was evaluated for inhibitory activity commercial enzyme xanthine oxidase (XO) *in vitro*.

Methods. Bovine milk XO activity was assayed spectrophotometrically by measuring the unic formation from substrate xanthine.

Results. A significant inhibitory activity of the studied cyclodidepsipeptide on XO was observe occur in a dose-dependent manner.

Conclusions. 6-(Propan-2-yl)-3-methyl-morpholine-2,5-dione may give a promise to be used in treatment of gout and related primary or secondary hyperuricemic conditions.

Keywords: cyclodidepsipeptides, 6-(propan-2-yl)-3-methyl-morpholine-2,5-dione, xanthine inhibition

Acknowledgments: The financial support of this work by Ministry of Science and Technolog Development of Serbia (Projects OI 172044 and TR 31060) and National Science Fund of Bull (young researchers project DMU-03/66) is gratefully acknowledged.

P65 Comparative analysis of the antigenotoxicity of five selected 4-hydroxy-2H-chromen-2-derivatives: possible mechanism of action

Matić S¹, Stanić S¹, Solujić S², Stanković N², Mladenović M², Mihailović V²

Department of Biology and Ecology, Faculty of Science, University of Kragujevac, Serbia

²Department of Chemistry, Faculty of Science, University of Kragujevac, Serbia

Introduction. Coumarin and coumarin-related compounds have proved for many years to have nificant therapeutic potential. A large number of 4-hydroxycoumarins and their derivatives have synthesized and evaluated for their ability to play a positive role in the prevention of human and diseases. Still, their antigenotoxic potential is unknown.

Aim. In the present study we examined the capability of five substituted 4-hydroxy-2H-chromenderivatives to counteract genotoxicity induced by the ethyl methanesulfonate (EMS), well-established recessive lethal (SLRL) test on *Drosophila melanog* under *in vivo* conditions. In addition, the molecular docking experiments were performed to the binding mode of coumarin compounds into deoxyribonucleic acid (DNA) and to investigate possible mechanism(s) of antigenotoxic action of selected 4-hydroxycoumarin derivatives.

Methods. Three days old Canton S males were treated with the potent mutagen EMS along concentration of 0.75 ppm, as well as in combination with one of the five 4-hydroxycounamely diethyl 2-(1-(4-hydroxy-2-oxo-2H-chromen-3-yl)ethylidene)malonate (2b), 3-(1-(4-hydroxy-2-oxo-2H-chromen-3-yl)ethylidene)malonate (2b), 3-(

2H-chromen-3-yl)ethylidene)pentane-2,4-dione (6b), 4-(4-(4-hydroxy-2-oxo-2H-chromen-3-yl) 2H-chromen-3-yl)enzenesulfonic acid (4c), 4-hydroxy-3-(2-(2-nitrophenylamino)thiazol-4-yl)-2H-men-2-one (9c), (E)-4-hydroxy-3-(1-(m-tolylimino)ethyl)-2H-chromen-2-one (5d), in concentration ppm.

Lecreased after post-treatments with coumarins. The maximum reduction was observed after post-ments with 2b, 6b, 4c, and 5d. By the formation of hydrogen bonds or electrostatic interactions with DNA guanine, tested coumarins prevent EMS induced alkylation.

dusion. The results indicate, in addition to its well documented action on development, a protective five 4-hydroxycoumarins under the action of a strong mutagen, such as EMS.

words: antigenotoxicity; *Drosophila melanogaster*; 4-hydroxycoumarins

nowledgments: This study was financially supported by the Serbian Ministry of Education and accept the Republic of Serbia, Grants No. III43004 and III41010.

P66 Pharmaceutical care - the right way for professionalism

Lova V¹, Andreevska K², Grekova D², Dimitrov M¹
Lulty of Pharmacy, Medical University. Sofia, Bulgaria
Lulty of Pharmacy, Medical University, Plovdiv, Bulgaria

reduction. Pharmaceutical care is the responsible provision of drug therapy for the purpose of leving definite outcomes that improve a patient's quality of life. Pharmaceutical care involves the less through which a pharmacist cooperates with a patient and other professionals in designing, mementing, and monitoring a therapeutic plan that will produce specific therapeutic outcomes for patient. This in turn involves three major functions:

ientifying potential and actual drug-related problems,

solving actual drug-related problems, and

reventing drug-related problems.

main benefit in pharmaceutical care is a contact based on trust in which the patient grants authority provider, and the provider gives competence and commitment to the patient.

The main aim of this study is to assess what would be the three priorities for Bulgaria in the fields safety and quality of pharmaceutical care.

thods. A standard questionnaire was applied to 150 pharmacists

wults. More than 70% of the pharmacists know the idea, but only 20% a willing to work in accorace to its principles. The main reasons for that are revealed.

words: Bulgaria, pharmaceutical care, pharmacy practice, priority

P67 The application of new kinetic-spectrophotometric method for determination of metronidazole in pharmaceutical formulation

lijkovic V1, Bojanic V2, Bojanic Z2, Sokolovic D2, Kostic D3, Rakic V4

Pharmacy of Prokuplje, Ratka Pavlovica 1, Prokuplje, Serbia

Faculty of Medicine, University of Nis, Serbia

Faculty of Sciences and Mathematics, The University of Nis, Nis, Serbia

College of Agriculture and Food Technology, Prokuplje, Serbia

troduction. Metronidazole [2-(2-methyl-5-nitro-1H- imidazol-1-yl) ethanol] is an amebicide, ntiprotozoal and antibiotic effective against anaerobic bacteria and certain parasites. Review of Literature for MND analysis revealed that several existing methods including different technique such